Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards' heart valve boosted by trials

This article was originally published in Clinica

Executive Summary

Results of two studies have backed Edwards Lifesciences' Sapien transcatheter heart valve, when delivered with the Ascendra transapical delivery system. Interim results from 67 patients in the PARTNER EU registry showed a 30-day survival rate of 82%, and a six-month survival rate of 56%. Furthermore, results from a post-marketing registry, SOURCE, showed a 30-day survival rate of 88% in the 309 cases evaluated. The data were presented at the annual meeting of the European Association for Cardio-Thoracic Surgery, held in Lisbon, Portugal in early September.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel